Two novel regimens showed significant anti-tumor activity in patients with neuroblastoma.
An RNA assay for common gene fusions is now validated and available to guide patients with cancer to clinical trials and through drug treatment options.
Serum levels of carbonic anhydrase IV (sCAIX) were associated with improved pathologic complete response rates.
Nearly half of patients with advanced cancer treated with FDA-approved therapies had alterations in circulating tumor DNA (ctDNA).
Single-cell RNA-sequencing can resolve the heterogeneity of both malignant and non-malignant tumor components.
MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.
Funding, informatics system, clinical data capture, and European data protection legislation were considered the greatest barriers to effective data sharing.
Neoadjuvant docetaxel plus carboplatin and trastuzumab followed by pertuzumab (TCH+P) was associated with improved pathologic complete response rate .
Adding lapatinib to trastuzumab plus weekly paclitaxel after an anthracycline was not beneficial.
Substituting Nab-paclitaxel in Anthracycline Regimen Did Not Significantly Improve pCR in HER2-negative Breast CancerJune 07, 2016
Replacing paclitaxel with nab-paclitaxel in an anthracycline regimen failed to significantly improve the pathologic complete response rate.
Intermittent docetaxel could be an option for patients with CRPC.
Weekly paclitaxel plus bevacizumab significantly improved progression-free survival and objective response rate in NSCLC.
A Web application called Moovcare that guides follow-up improved survival for patients with advanced lung cancer after receiving initial therapy.
Adding enzalutamide to abiraterone acetate and leuprolide acetate does not appear to be effective for the treatment of localized high-risk prostate cancer.
A hypofractionated radiotherapy regimen administered in 20 fractions over 4 weeks was noninferior in patients with localized prostate cancer.
In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.
Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.
Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.
Extending Hormone Therapy to 10 Years May Reduce Breast Cancer Recurrence Without Negatively Affecting QoLJune 05, 2016
Extending aromatase inhibitor therapy for 5 years beyond an initial 5 years resulted in a 34% reduction in recurrence in early-stage breast cancer.
Cbimetinib and atezolizumab was well tolerated and demonstrated encouraging clinical activity in microsatellite stable colorectal cancer (CRC).
Nivolumab with or without ipilimumab was well tolerated in most patients with high microsatellite instability metastatic colorectal cancer (mCRC).
In patients with stage I, II, or III colon cancer, high Immunoscore was associated with significantly longer time to recurrence.
More transparency regarding the costs of various treatment regimens in real time is needed to "choose wisely" for patients, providers, and payers.
There were no effective therapeutic options for advanced thyroid cancer until 5 years ago.
In patients with metastatic urothelial carcinoma treated with atezolizumab, low peripheral T-cell receptor (TCR) clonality was associated with survival.
WNT/β-catenin pathway signaling is associated with T cell exclusion and is activated in most human solid tumors, including colon, kidney, and lung tumors.
Patients with non-small cell lung cancer (NSCLC) treated with anti-programmed cell death-1 (anti-PD-1) therapy generally do not benefit from treatment.
First-line therapy with nivolumab in combination with ipilimumab demonstrated clinical activity in non-small cell lung cancer (NSCLC).
Older patients receiving concurrent chemoradiotherapy for stage III non-small cell lung cancer (NSCLC) had worse overall survival.
Geriatric assessmentmay improve the selection of older patients with stage III non-small cell lung cancer (NSCLC).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib